Literature DB >> 18521247

Aggressive fibromatosis: evidence for a stable phase.

G Mitchell1, J M Thomas, C L Harmer.   

Abstract

Purpose. Aggressive fibromatosis (AF) is an uncommon locally infiltrating benign disease of soft tissue for which treatment comprises complete surgical resection. Radiotherapy can be given postoperatively if the margin is incompletely resected. If the tumour is inoperable radiotherapy provides an alternative treatment. Hormone therapy and cytotoxic chemotherapy have also been used for unresectable or recurrent disease. All treatment modalities carry an associated morbidity. We believe that the natural history of aggressive fibromatosis may include a period of stable disease without progression, during which time, treatment is not always necessary.Patients and methods. We present a retrospective review of 42 patients referred to the Royal Marsden Hospital between 1988 and 1995 with aggressive fibromatosis. Evidence of periods of stable disease and the relationship to delivered treatment was obtained from the case notes, including the natural history prior to referral to our institution. Stable disease was defined as a period of no objective progression for 6 months or longer.Results. Seventeen patients could be assessed for stable disease and all (100%) experienced at least one episode of stable disease, eight of whom whilst receiving hormonal or cytotoxic therapy. Of the 23 patients who could not be assessed for stable disease, as they underwent surgery at presentation or recurrence of disease, only 2 had persisting disease at last follow-up. Both of these patients had had positive surgical resection margins.Discussion. This study demonstrates the variable natural history of AF, which can include a substantial period of stable disease in a significant number of patients. A less aggressive approach to the management of AF may therefore be appropriate, particularly if a subgroup of patients who are likely to experience a period of stable disease can be identified.

Entities:  

Year:  1998        PMID: 18521247      PMCID: PMC2395399          DOI: 10.1080/13577149877902

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  20 in total

1.  The desmoid tumor. Not a benign disease.

Authors:  M C Posner; M H Shiu; J L Newsome; S I Hajdu; J J Gaynor; M F Brennan
Journal:  Arch Surg       Date:  1989-02

2.  Radiotherapy and conservative surgery in the management of musculo-aponeurotic fibromatosis.

Authors:  A D Stockdale; A M Cassoni; M A Coe; R H Phillips; K A Newton; G Westbury; D H Mackenzie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-10       Impact factor: 7.038

3.  Case report. Infiltrative fibromatosis: a rare cause of fatal haemorrhage.

Authors:  M A Ashby; C L Harmer; J A McKinna; S C Lennox
Journal:  Clin Radiol       Date:  1986-03       Impact factor: 2.350

4.  Radiation therapy in the treatment of aggressive fibromatoses.

Authors:  H M Greenberg; R Goebel; R R Weichselbaum; J S Greenberger; J T Chaffey; J R Cassady
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-03       Impact factor: 7.038

5.  Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature.

Authors:  D W Easter; N A Halasz
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

6.  Management of desmoid tumors.

Authors:  J G McKinnon; J P Neifeld; S Kay; G A Parker; W C Foster; W Lawrence
Journal:  Surg Gynecol Obstet       Date:  1989-08

7.  Remission of rapidly growing desmoid tumors after tamoxifen therapy.

Authors:  B Kinzbrunner; S Ritter; J Domingo; C J Rosenthal
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

8.  Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors).

Authors:  K D Kiel; H D Suit
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

9.  The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor.

Authors:  J J Reitamo; T M Scheinin; P Häyry
Journal:  Am J Surg       Date:  1986-02       Impact factor: 2.565

10.  Desmoid tumors: local control and patterns of relapse following radiation therapy.

Authors:  S A Leibel; W M Wara; D R Hill; E G Bovill; A A de Lorimier; J H Beckstead; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038

View more
  7 in total

1.  Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis.

Authors:  Fábio Guilherme Campos; Carlos Augusto Real Martinez; Marleny Novaes; Sérgio Carlos Nahas; Ivan Cecconello
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

2.  Extra-abdominal desmoid tumors associated with familial adenomatous polyposis.

Authors:  George T Calvert; Michael J Monument; Randall W Burt; Kevin B Jones; R Lor Randall
Journal:  Sarcoma       Date:  2012-06-03

3.  Management of advanced adult soft tissue sarcoma.

Authors:  Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003

4.  Current perspectives on desmoid tumors: the mayo clinic approach.

Authors:  Siddharth B Joglekar; Peter S Rose; Franklin Sim; Scott Okuno; Ivy Petersen
Journal:  Cancers (Basel)       Date:  2011-08-08       Impact factor: 6.639

5.  Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention.

Authors:  Danique L M van Broekhoven; Dirk J Grünhagenl; Thijs van Dalen; Frits van Coevorden; Han J Bonenkamp; Lukas B Been; Marc H A Bemelmans; Sander D S Dijkstra; Chiara Colombo; Alessandro Gronchi; Cornelis Verhoef
Journal:  BMC Cancer       Date:  2016-08-26       Impact factor: 4.430

6.  Aggressive Fibromatosis, Clinicopathologic Findings of 25 Cases; A Single-Center Experience and Review of the Literature.

Authors:  Bita Geramizadeh; Fateme Jalali
Journal:  Iran J Pathol       Date:  2017-01-29

7.  Factors Associated with Disease Stabilization of Desmoid-Type Fibromatosis.

Authors:  Yongsung Kim; Mamer S Rosario; Hwan Seong Cho; Ilkyu Han
Journal:  Clin Orthop Surg       Date:  2020-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.